Effects of in vitro antibiotic resistance on treatment: Bismuth-containing regimens

Canadian Journal of Gastroenterology

Volumn 14, Issue 10, 2000, Pages 885-889

  Chiba, N ^a  

^a Surrey GI Clinic   (Canada)

Author keywords

Antimicrobial susceptibility; Bismuth; Clarithromycin; Eradication; Helicobacter pylori; Metronidazole

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CLARITHROMYCIN; ENZYME INHIBITOR; GLYCOSIDASE; IMIDAZOLE DERIVATIVE; METRONIDAZOLE; NITROIMIDAZOLE; PHOSPHOLIPASE; PROTEINASE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE; TRIACYLGLYCEROL LIPASE;

ANTIBIOTIC RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; ERADICATION THERAPY; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TREATMENT OUTCOME;

EID: 0034505948     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/709640     Document Type: Article

References (48)

1. Unidentified curved bacillus on gastric epithelium in active chronic gastritis
2. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease
3. Canadian Helicobacter pylori Consensus Conference update: Infections in adults
4. Current European concepts in the management of Helicobacter pylori infection. The Mäastricht Consensus report
5. SM International Update Conference on Helicobacter pylori
6. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
7. Review article: Safety of bismuth in the treatment of gastrointestinal diseases
8. Colloidal bismuth subcitrate in peptic ulcer - A review
9. Bismuth therapy in gastrointestinal diseases
10. The mode of action of colloidal bismuth subcitrate
11. Prevention of nitroimidazole resistance in Campylobacter pylori by administration of colloidal bismuth subnitrate: Clinical and in vitro studies
12. Evaluation of various multi-drug eradication regimens for Helicobacter pylori
13. Metronidazole susceptibility testing for Helicobacter pylori: Comparison of disk, broth, and agar dilution methods and their clinical relevance
14. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori
15. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease
16. Drug therapy of H pylori infection: A meta-analysis
17. Eradication of Helicobacter pylori: An objective assessment of current therapies
18. Review article: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence
19. Bismuth, metronidazole and tetracycline (BMT) +/-acid suppression in H pylori eradication: A meta-analysis
20. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection
21. One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection
22. Weekend lansoprazole - Quadruple therapy for Helicobacter pylori infection
23. 4-day lansoprazole quadruple therapy: A highly effective cure for Helicobacter pylori infection
24. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection
25. Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection
26. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: Results of a randomized prospective single-centre study
27. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection
28. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection
29. Ranitidine bismuth citrate: A novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture
30. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate
31. The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics
32. Ranitidine bismuth citrate can overcome in vitro antibiotic resistance in Helicobacter pylori
33. The synergistic interaction between GR122311X and clarithromycin against Helicobacter
34. Overcoming clarithromycin resistance with the combination of clarithromycin and ranitidine bismuth citrate
35. Ranitidine bismuth citrate enhances clarithromycin activity against clinical isolates of H pylori
36. Synergism study of ranitidine bismuth citrate and metronidazole against metronidazole resistant H. pylori clinical isolates
37. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: A randomized, clinical trial
38. Ranitidine bismuth citrate in combination with clarithromycin is effective against H. pylori strains with susceptible or intermediate clarithromycin sensitivity
39. Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin
40. Development of clarithromycin resistance is 2.7 times less likely with ranitidine bismuth citrate than with omeprazole
41. Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection
42. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): A randomized comparison between two 7-day triple therapies and a 14-day dual therapy
43. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: A prospective randomized controlled trial
44. Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days
45. The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
46. Ranitidine bismuth citrate with clarithromycin given alone or with metronidazole for 7 days effectively eradicates H. pylori
47. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection